Onkologie. 2020:14(1):26-31 | DOI: 10.36290/xon.2020.009
News in the treatment of metastatic renal cancer
- Interní hematologická a onkologická klinika, FN Brno
The Czech Republic has the highest incidence of renal cancer. The most common histology type is clear cell renal cancer. For early stage cancer, radical nefrectomy is a curative approach. Until recently, for the first line treatment of metastatic renal cancer, tyrosin-kinase inhibitor (TKI) had been the treatment of choice. For patients in the poor prognosis group, mTOR (mammalian target of rapamycin) inhibitor temsirolimus was indicated, but it had not been associated with any substantial benefit to the patient. By contrast, based on the results of several clinical trials presented recently, modern immunotherapy with check-point inhibitors (CPI) is already registered in first line settings in a combination with other CPI or TKI. From the results to date, it is clear, that these combinations are beneficial particularly among patients with intermediate and poor prognosis.
Keywords: metastatic renal cancer, tyrosin-kinase inhibitor, immunotherapy.
Received: December 20, 2019; Revised: January 19, 2020; Accepted: January 19, 2020; Prepublished online: January 19, 2020; Published: March 1, 2020 Show citation
References
- Dusek L, Muzik J, Maluskova D, et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol. 2014; 27(6): 406-423.
Go to original source... 
Go to PubMed... - Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita [2005]. Dostupné z: www.svod.cz [cit. 2019-10-09].
- Lenis AT, Donin NM, Johnson DC, et al. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2018; 199(1): 43-52. Go to original source... Go to PubMed...
- Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicen - ter study. J Clin Oncol 2009; 27(34): 5794-5799. Go to original source... Go to PubMed...
- Zhoubný novotvar ledviny (C64). Modrá kniha České onkologické společnosti. 25. aktualizace. Brno: Masarykův onkologický ústav, 2019. Platnost od 1. 3. 2019.
- Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019; 20(10): 1370-1385. Go to original source... Go to PubMed...
- McDermott DF, Choueri TK, Motzer RJ, et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol. 2019; 37: 4513. Go to original source...
- Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12): 1116-1127. Go to original source... Go to PubMed...
- Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12): 1103-1115. Go to original source... Go to PubMed...
- Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019; 393(10189): 2404-2415. Go to original source... Go to PubMed...